Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy
Kazuho Miyashita(Fujisawa City Hospital), Yoshiaki Ishigatsubo(Yokohama City University), Masataka Taguri(Yokohama City University), Hirotaka Takasaki(Kanagawa Prefectural Hospital Organization), Takayoshi Tachibana(Yokohama City University), Naoto Tomita(St. Marianna University School of Medicine), Sachiya Takemura(Osaka Ekisaikai Hospital), Yasufumi Ishiyama(Kanagawa Prefectural Hospital Organization), Yoshimi Ishii(Yokohama City University Medical Center), Katsumichi Fujimaki(Fujisawa City Hospital), Wataru Yamamoto(Yokohama City University Medical Center), Ayumi Numata(Yokohama City University Medical Center), Yuki Nakajima(Fujisawa City Hospital), Takuya Miyazaki(Kanagawa Prefectural Hospital Organization), Rika Sakai(Yokohama City University Medical Center), Kenji Matsumoto(Keio University), Yukako Hattori(Yokohama City University), Shigeki Motomura(Kanagawa Prefectural Hospital Organization), Chizuko Hashimoto(Yamato Municipal Hospital), Etsuko Yamazaki(Yokohama City University), Taisei Suzuki(Hiratsuka City Hospital)
Cited by 35
Related Papers
Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study
|Clinical Infectious Diseases|2015|149
Nucleosides and nucleotides. 100. 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabinofuranosylcytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside
|Journal of Medicinal Chemistry|1991|85
Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib
|Hepatology Research|2011|77
Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large <scp>B</scp>‐cell lymphoma in the rituximab era
|European Journal Of Haematology|2013|58